A

Amgen

Makes biotech medicines for serious illnesses

Associate Information Systems Business Analyst

Full-TimeUpdated on 10/24/2026
No salary listed
Mid, Senior
Bachelor's
Hyderabad, Telangana, India
In Person
Data & AnalyticsBusiness Intelligence

About the job

Requirements
  • A bachelor's degree in Information Systems, Computer Science, Engineering, Business Administration, Data Analytics, or a related field.
  • Three to five years of experience in Business Analysis, Business Intelligence, Reporting and Analytics, Data Analysis, or a related role.
  • Hands-on experience developing dashboards and reports using Tableau and/or Power BI.
  • Knowledge of Power BI DAX, Power Query, Tableau calculations, Level of Detail expressions, and dashboard optimization techniques.
  • Experience building KPI dashboards, executive scorecards, operational reports, and analytical visualizations.
  • Strong SQL skills for data extraction, analysis, validation, and reporting.
  • Knowledge of SaaS and COTS applications to support RunOps for multiple applications.
  • Experience gathering, documenting, validating, and managing business and reporting requirements.
  • Ability to translate business needs into effective data, dashboard, and analytics solutions.
  • Experience creating user stories, acceptance criteria, process flows, data requirements, and functional specifications.
  • Strong understanding of dashboard design, data visualization, usability, and data-storytelling principles.
  • Experience with relational databases, large datasets, data modeling concepts, data quality, and reconciliation.
  • Experience publishing, maintaining, and supporting dashboards in enterprise environments.
  • Experience supporting user acceptance testing, defect management, business validation, and release activities.
  • Experience working in Agile or Scrum delivery teams and using Jira, Confluence, Azure DevOps, or similar tools.
  • Strong stakeholder management, analytical, problem-solving, communication, and presentation skills.
  • Ability to work effectively with global, virtual, and cross-functional teams.
  • Strong analytical and critical thinking abilities.
  • Ability to simplify complex data and technical concepts for business audiences.
  • High degree of ownership, accountability, initiative, and attention to detail.
  • Collaborative mindset with a focus on shared outcomes and business value.
  • Ability to manage multiple priorities in a dynamic, global, and matrixed environment.
  • Curiosity and willingness to learn new technologies and business domains.
Responsibilities
  • Partner with business stakeholders to understand processes, challenges, reporting needs, and business objectives.
  • Gather, analyze, document, and validate business, functional, data, and reporting requirements.
  • Facilitate stakeholder discussions, workshops, and requirements-gathering sessions.
  • Translate business needs into user stories, acceptance criteria, process flows, data requirements, and functional specifications.
  • Collaborate with Product Owners and delivery teams to prioritize requirements and support backlog refinement.
  • Identify opportunities for process improvement, automation, standardization, and efficiency gains.
  • Ensure alignment between business expectations and delivered solutions.
  • Support user acceptance testing, business validation, and defect triage.
  • Design, develop, enhance, and maintain dashboards and reports using Tableau and/or Power BI.
  • Partner with stakeholders to define KPIs, metrics, scorecards, calculations, and reporting requirements.
  • Create visualizations that communicate business performance, trends, and operational insights.
  • Develop executive dashboards, operational reports, and analytical solutions for different stakeholder groups.
  • Perform data analysis to identify trends, risks, opportunities, and actionable business insights.
  • Ensure dashboard accuracy through data validation, reconciliation, and quality checks.
  • Publish, maintain, monitor, and support dashboards in enterprise environments.
  • Optimize dashboard performance, usability, accessibility, and adoption.
  • Work with data engineers, developers, architects, and technical teams to understand source systems, data structures, and integration needs.
  • Support data mapping, validation, reconciliation, and root-cause analysis across multiple data sources.
  • Assist in defining business rules, calculations, transformations, and reporting datasets.
  • Troubleshoot reporting, dashboard, and data-related issues and coordinate resolution with technical teams.
  • Ensure analytics solutions meet business, quality, security, and compliance expectations.
  • Participate in Agile ceremonies, including sprint planning, backlog refinement, reviews, and retrospectives.
  • Support functional testing, data validation, defect management, release readiness, and post-release verification.
  • Create and maintain requirements, dashboard documentation, data definitions, and user guides.
  • Deliver dashboard demonstrations and solution walkthroughs to business and technical stakeholders.
  • Stay current with business intelligence, analytics, visualization, and AI-enabled reporting capabilities.
Desired Qualifications
  • Experience in life sciences, biotechnology, pharmaceutical, healthcare, EHSS, manufacturing, or another regulated industry.
  • Experience supporting Environmental, Health and Safety, Sustainability, Quality, Compliance, Operations, or Corporate functions.
  • Experience with cloud-based data and analytics platforms such as Azure, AWS, Databricks, or Snowflake.
  • Understanding of data warehousing, ETL/ELT processes, APIs, integrations, and enterprise reporting architectures.
  • Familiarity with Python or another analytics-related programming language.
  • Exposure to AI-assisted analytics, reporting, or business productivity tools.
  • Experience supporting enterprise-scale reporting solutions and globally distributed business teams.
  • Experience with Generative AI products and solutions.
  • Understanding of LLMs, copilots, chatbots, and AI assistants.
  • Knowledge of prompt engineering concepts.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.